Share & more
Millions of people living with HIV/AIDS in Africa and the Caribbean will benefit from the development of a single-dose anti-AIDS drug, three major US pharmaceutical companies announced in a joint statement.
Bristol-Myers Squibb, Gilead Sciences, and Merck and Company said they were pursuing research that would combine three of their HIV medicines into a single tablet, to make treatment in developing countries both easier and cheaper.
The announcement was made at the same time as a pledge by the US to speed up the review process for such drugs.
"We are clearing the way to quickly deliver quality, life-saving HIV/AIDS drugs to people who desperately need them in developing countries," US Health and Human Services Secretary Tommy Thompson was quoted as saying by the South African Press Association.
This article was produced by IRIN News while it was part of the United Nations Office for the Coordination of Humanitarian Affairs. Please send queries on copyright or liability to the UN. For more information: https://shop.un.org/rights-permissions
